Skip to content
OpenCapital
Get started

Denali Therapeutics Inc. DNLI Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
——

Other financials

Income statement

See full
Revenue-—
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.93B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0×0.0×
Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
Denali Therapeutics Inc. (DNLI) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $22.55M in Q1 2026.
How has Denali Therapeutics Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
Denali Therapeutics Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 1.6% year-over-year, from $22.19M to $22.55M.
What is the long-term trend for Denali Therapeutics Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 10.5% compound annual growth rate (CAGR), from $12.96M to $21.33M.